Ferrer-Alcón Marcel, La Harpe Romano, García-Sevilla Jesús A
Clinical Research Unit, Department of Psychiatry, University of Geneva, H.U.G., Belle-Idée (Les Voirons), CH-1225 Chêne-Bourg, Geneva Switzerland.
Brain Res Mol Brain Res. 2004 Feb 5;121(1-2):114-22. doi: 10.1016/j.molbrainres.2003.11.009.
The homologous regulation of opioid receptors, through G protein-coupled receptor kinases (GRKs) and beta-arrestins, is an initial step in the complex molecular mechanisms leading to opiate tolerance and dependence. This study was designed to evaluate in parallel the contents of immunolabeled micro-opioid receptors (glycosylated proteins), two representative GRKs (GRK 2 and GRK 6) and beta-arrestin-2 in brains of opiate addicts who had died of an opiate overdose (heroin or methadone). The immunodensities of micro-opioid receptors were decreased (66 kDa protein: 24%, n=24, P<0.0001; 85 kDa protein: 16%, n=24, P<0.05) in the prefrontal cortex of opiate addicts compared with sex-, age-, and PMD-matched controls. This down-regulation of brain micro-opioid receptors was more pronounced in opiate addicts dying of a heroin overdose (27-30%, n=13) than in those who died of a methadone overdose (5-16%, n=11). In the same brains, significant decreases in the immunodensities of GRK 2 (19%, n=24, P<0.05), GRK 6 (25%, n=24, P<0.002) and beta-arrestin-2 (22%, n=24, P< 0.0005) were also quantitated. In contrast, the content of alpha-internexin (a neuronal marker used as a negative control) was not changed in brains of opiate addicts. In these subjects, there was a significant correlation between the densities of GRK 6 and beta-arrestin-2 (r=0.63, n=24, P=0.001), suggesting that both proteins are regulated in a coordinated manner by opiate drugs in the brain. The results indicate that opiate addiction in humans (tolerant state) is associated with down-regulation of brain micro-opioid receptors and regulatory GRK 2/6 and beta-arrestin-2 proteins. These molecular adaptations may be relevant mechanisms for the induction of opiate tolerance in brains of opiate addicts.
通过G蛋白偶联受体激酶(GRKs)和β-抑制蛋白对阿片受体的同源调节,是导致阿片耐受和依赖的复杂分子机制的初始步骤。本研究旨在同时评估死于阿片过量(海洛因或美沙酮)的阿片成瘾者大脑中免疫标记的微阿片受体(糖基化蛋白)、两种代表性GRKs(GRK 2和GRK 6)以及β-抑制蛋白-2的含量。与性别、年龄和死后间隔时间匹配的对照组相比,阿片成瘾者前额叶皮质中微阿片受体的免疫密度降低(66 kDa蛋白:降低24%,n = 24,P < 0.0001;85 kDa蛋白:降低16%,n = 24,P < 0.05)。死于海洛因过量的阿片成瘾者(27 - 30%,n = 13)大脑中微阿片受体的这种下调比死于美沙酮过量的成瘾者(5 - 16%,n = 11)更明显。在同一批大脑中,还定量检测到GRK 2(降低19%,n = 24,P < 0.05)、GRK 6(降低25%,n = 24,P < 0.002)和β-抑制蛋白-2(降低22%,n = 24,P < 0.0005)的免疫密度显著降低。相比之下,α-中间丝蛋白(用作阴性对照的神经元标志物)在阿片成瘾者大脑中的含量没有变化。在这些受试者中,GRK 6和β-抑制蛋白-2的密度之间存在显著相关性(r = 0.63,n = 24,P = 0.001),表明这两种蛋白在大脑中受阿片类药物的协同调节。结果表明,人类阿片成瘾(耐受状态)与大脑微阿片受体以及调节性GRK 2/6和β-抑制蛋白-2的下调有关。这些分子适应性变化可能是阿片成瘾者大脑中诱导阿片耐受的相关机制。